How geothermal water scale inhibitor dosage changes with brine chemistry

Geothermal scale-control programs fail most often when a single inhibitor dose is carried from one well, separator train, or operating season into another without rechecking the brine. A geothermal water scale inhibitor is not dosed against “geothermal water” in general. It is dosed against the minerals that become supersaturated after pressure release, flashing, cooling, mixing, pH change, or contact with oxygen.

For technical evaluation, the practical question is not “What is the standard dosage?” It is: which deposition mechanism is dominant at the point of risk, how rapidly does it develop, and how much active chemistry is needed to delay or control it under the actual temperature, residence time, and flow conditions? A brine with moderate calcium may demand more treatment than a harder brine if it experiences a stronger pH shift or carbon dioxide loss. Likewise, a silica-rich fluid can require a completely different treatment strategy from one dominated by carbonate scale.

Start with the scale risk after the process change

Raw wellhead analysis is necessary, but it is not enough. Scale may not form in the reservoir fluid itself. It often appears after flashing reduces pressure, carbon dioxide leaves solution, temperature changes, or produced brine is blended with make-up water, condensate, or another stream. Dosage evaluation should therefore focus on the water chemistry expected at the separator outlet, heat exchanger inlet, reinjection line, or other deposition-prone point.

Calcium carbonate is a common example. As dissolved carbon dioxide is released during flashing, pH can rise and carbonate availability changes. Calcium that was stable in the pressurized brine may then precipitate quickly. In this case, inhibitor demand is driven by calcium concentration, alkalinity or inorganic carbon balance, pH movement, temperature, and the extent of degassing. A dose selected from calcium alone can be misleading.

Sulfate scale follows a different logic. Barium sulfate and strontium sulfate can form at very low solubility levels, especially where incompatible waters mix. Even a relatively small concentration of barium or strontium can become operationally significant when sulfate enters through dilution water, process additives, leakage, or a different produced-water stream. The inhibitor dose must be evaluated against the mixing ratio and the resulting ion product, not simply against the composition of either source water.

Silica requires still another approach. Its deposition behavior depends on dissolved silica concentration, temperature, pH, polymerization tendency, residence time, and the presence of metal ions or suspended solids that provide nucleation sites. When silica polymerizes or combines with iron, aluminum, calcium, or magnesium, treatment may need stronger dispersancy and deposit-control capability rather than a higher dose of a carbonate-focused inhibitor alone.

Which brine parameters most directly change dosage?

A useful evaluation separates the chemistry into four groups: scale-forming ions, conditions that alter solubility, competing contaminants, and operational variables. All four can change the effective dose requirement.

• Calcium, magnesium, barium and strontium: These ions identify potential carbonate or sulfate deposition routes. Higher concentration generally increases treatment demand, but the dose response is rarely linear because saturation can rise sharply after flashing or mixing.
• Bicarbonate, carbonate and dissolved carbon dioxide: Their importance is greatest where pressure reduction changes pH and carbonate equilibrium. A rapid flash process can require a different injection point or higher residual inhibitor concentration than a closed-loop heat-transfer section.
• Sulfate: Sulfate should be evaluated with barium and strontium together. The risk can increase abruptly after water blending, even when each individual stream appears manageable.
• Silica and metal contaminants: Dissolved silica, iron, aluminum, manganese, and suspended solids can promote complex mixed deposits. Iron oxidation can also produce particulate fouling that consumes or interferes with the treatment program.
• pH, temperature and salinity: These influence solubility, ion activity, inhibitor performance, and corrosion behavior. High salinity can alter how ionic species behave; a formula that performs in lower-salinity laboratory water may not retain the same margin in concentrated geothermal brine.
• Flow velocity and residence time: A deposit-prone dead leg, low-flow branch, or long reinjection pipeline may need a different residual treatment target from a high-velocity main line, even with identical chemistry.

For this reason, dosage should be expressed as active inhibitor concentration at the relevant treatment location, not only as liters of commercial product per day. Commercial products can have different active contents, densities, and dilution practices. Comparing consumption only by product volume can obscure whether a change in performance comes from chemistry, dosage, or product strength.

Higher hardness does not automatically mean a proportionally higher dose

It is tempting to increase dosage in direct proportion to calcium hardness or total dissolved solids. That shortcut is unreliable in geothermal service. Threshold inhibitors work by interfering with crystal formation and growth, so the required concentration depends on the degree of supersaturation and the kinetics of precipitation. A modest chemistry shift that moves the fluid across a precipitation threshold can produce a much larger operational change than a substantial increase in dissolved calcium that remains below that threshold.

Temperature creates another common misunderstanding. Higher temperature may reduce the solubility of certain scales, accelerate deposition kinetics, or challenge the stability of some treatment chemistries. Yet the hottest point is not always the point requiring the highest dose. If scale forms mainly after flash separation, the correct control point may be downstream of the wellhead where carbon dioxide loss and pH change have already occurred. Injection upstream may still be appropriate when sufficient mixing and residence time are needed, but it should be justified by process conditions rather than convenience.

In high-silica brines, simply increasing an organophosphorus inhibitor dose may not solve polymeric silica fouling. Excess treatment can raise chemical cost without preventing the dominant mechanism. Evaluators should first distinguish amorphous silica deposition from calcium silicate, metal silicate, carbonate, sulfate, or mixed mineral deposits. Deposit analysis, when available, is more useful than assumptions based on a single water-analysis result.

Use laboratory work to establish a dose window, then test the operating margin

A practical program usually begins with representative brine sampling and a defined simulation of the process conditions. The laboratory objective is not to identify one universally correct number. It is to establish a dose window that suppresses precipitation under expected chemistry, then determine whether the selected dose retains a margin when the process varies.

The test design should reproduce the factors most likely to trigger deposition: pressure-release conditions, temperature profile, mixing ratio, pH shift, exposure to oxygen where relevant, and residence time. For carbonate and sulfate risks, the test should assess precipitation tendency and inhibitor response across several active concentrations. For silica-containing waters, filtration behavior, turbidity, particle formation, and deposit character may be as informative as a single dissolved-silica reading.

One candidate chemistry for calcium-containing geothermal systems is 1-Hydroxy Ethylidene-1,1-Diphosphonic Acid (HEDP). HEDP can complex metal ions, particularly calcium, and offers threshold scale-inhibition behavior. Its reported stability at elevated temperature and under relatively high-pH conditions can make it a relevant component for evaluation where carbonate control, metal-ion complexation, and compatibility with other water-treatment agents are needed. It should still be screened against the actual brine and treatment temperature, especially where silica, barium sulfate, or substantial iron contamination contributes to the deposit.

Compatibility testing matters when the program includes more than one chemical. Geothermal operations may require a combination of scale inhibitor, dispersant, corrosion-control chemistry, oxygen scavenger, biocide, or pH-adjustment chemical depending on the process. The selected treatment should remain soluble and functional after dilution and should not create a new precipitate when it contacts brine with high hardness or salinity.

Field optimization should follow deposition indicators, not chemical consumption alone

Once an initial dose is selected, field adjustment should be tied to measurable operating indicators. These may include differential pressure across heat-transfer equipment or filters, heat-transfer performance, injection-line pressure trend, solids accumulation, separator condition, scale coupon inspection, and chemical residual where an appropriate analytical method is available. A lower apparent scale rate after increasing dose is useful only when operating temperature, flow, water source, and maintenance history are considered at the same time.

Sampling frequency should increase after a change in well contribution, reinjection-water blending, separator pressure, flash conditions, acidification activity, or plant operating temperature. These changes can alter brine chemistry enough to invalidate the original dosage basis. Seasonal groundwater intrusion or variable condensate return may have the same effect in systems with unstable water balance.

For procurement and technical approval, require the supplier’s recommended dose to be stated as active concentration, along with the assumed brine chemistry, temperature range, injection location, and deposit mechanism. A recommendation that does not identify these conditions is difficult to validate. The most defensible treatment program is one that links product selection, dose, injection point, and monitoring method to a defined scaling risk, then revises those settings when the brine or process changes.